Page 12 - Flipbook

PARP Inhibitors are Health Canada Approved or Under

Investigation for Prostate Cancer

Olaparib Rucaparib Veliparib Talazoparib Niraparib

MW 434.5 323.4 244.3 380.8 320.4

PARP1 IC 50 5 nM 0.65 nM 1.2 nM 0.56 nM 3.8 nM

PARP2 IC 50 1 nM 0.08 nM 0.41 nM 0.15 nM 2.1 nM

Trapping ++ ++ + ++++ +++

Monotherapy for mCRPC with a
deleterious or suspected
deleterious BRCA or ATM
Approved for
mutation(germline and/or No No No No
prostate cancer
somatic)

Prior treatment with new
hormonal agent*

*Eg, abiraterone, enzalutamide, darolutamide, or apalutamide

mCRPC, metastatic castration-resistant prostate cancer
Carney B et al. Nat Comm 2018;9:176.